IP Library Granted Patent US 9,630,948
Granted Patent B2
US 9,630,948 · App. 14/909,246 · Granted Apr 25, 2017

Compounds for enhancing the cognitive function

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,630,948
App. No.
14/909,246
Granted
Apr 25, 2017
Kind
B2
Abstract

The invention relates to 2-oxo-1-pyrrolidinyl triazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals for enhancing the cognitive function or to counteract cognitive decline.

Claims (24)

1. A compound of formula (I)

wherein

R 1 is either a 3,4,5-trifluorophenyl or a 3-cyanophenyl group;

R 2 is either cyano or chlorine;

or a tautomer, isomer or salt thereof.

2. The compound according to claim 1 , wherein the R 1 group of formula (I) is in a 4R configuration.

3. The compound according to claim 2 , wherein the R 1 group is a 3,4,5-trifluorophenyl moiety.

4. The compound according to claim 1 , wherein the R 1 group of formula (I) is in a 4S configuration.

5. The compound according to claim 4 , wherein the R 1 group is a 3,4,5-trifluorophenyl moiety.

6. The compound according to claim 1 , wherein the R 1 group is a 3,4,5-trifluorophenyl moiety.

7. The compound according to claim 1 that is

(4R)-1-[(5-chloro-1H-1,2,4-triazol-1-yl)methyl]-4-(3,4,5-trifluorophenyl)pyrrolidin-2-one;

1-{[(4R)-2-oxo-4-(3,4,5-trifluorophenyl)pyrrolidin-1-yl]methyl}-1H-1,2,4-triazole-5-carbonitrile; or

(+)-3-{1-[(5-chloro-1H-1,2,4-triazol-1-yl)methyl]-5-oxopyrrolidin-3-yl}benzonitrile.

8. A pharmaceutical composition containing a compound according to claim 1 together with a suitable pharmaceutically acceptable excipient.

9. A pharmaceutical composition containing a compound according to claim 2 together with a suitable pharmaceutically acceptable excipient.

10. A pharmaceutical composition containing a compound according to claim 7 together with a suitable pharmaceutically acceptable excipient.

11. A method of treating Alzheimer's disease in a human comprising administering to the human an effective amount of a compound according to claim 1 .

12. A method of treating Alzheimer's disease in a human comprising administering to the human an effective amount of a compound according to claim 2 .

13. A method of treating Alzheimer's disease in a human comprising administering to the human an effective amount of a compound according to claim 4 .

14. A method of treating Alzheimer's disease in a human comprising administering to the human an effective amount of a compound according to claim 6 .

15. A method of treating Alzheimer's disease in a human comprising administering to the human an effective amount of a compound according to claim 7 .

16. A method of treating Alzheimer's disease in a human comprising administering to the human an effective amount of a compound according to claim 3 .

17. A method of treating Alzheimer's disease in a human comprising administering to the human an effective amount of a compound according to claim 5 .

Assignments (4)
CHANGE OF NAME Recorded Mar 5, 2022
From: UCB BIOPHARMA SPRL
To: UCB BIOPHARMA SRL
Reel/Frame 059323/0175 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNOR NAME IN THE ASSIGNMENT DOCUMENT PREVIOUSLY RECORDED AT REEL: 044349 FRAME: 0206. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Mar 4, 2022
From: UCB PHARMA, S.A.
To: UCB BIOPHARMA SPRL
Reel/Frame 059320/0513 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 11, 2017
From: UCB PHARMA S.A.
To: UCB BIOPHARMA SPRL
Reel/Frame 044349/0206 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 2, 2017
From: MONTEL, FLORIAN; JNOFF, ERIC
To: UCB PHARMA, S.A.
Reel/Frame 041155/0938 →